Home » Stocks » SLGL

Sol-Gel Technologies Ltd. (SLGL)

Stock Price: $10.29 USD -0.15 (-1.44%)
Updated Jan 20, 2021 1:43 PM EST - Market open
Market Cap 240.13M
Revenue (ttm) 22.90M
Net Income (ttm) -24.61M
Shares Out 19.53M
EPS (ttm) -1.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $10.29
Previous Close $10.44
Change ($) -0.15
Change (%) -1.44%
Day's Open 10.51
Day's Range 10.26 - 10.77
Day's Volume 10,677
52-Week Range 5.88 - 14.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

NESS ZIONA, Israel, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializ...

GlobeNewsWire - 1 month ago

- PDUFA Goal Date Set for August 1, 2021

Zacks Investment Research - 1 month ago

Sol-Gel Technologies (SLGL) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Seeking Alpha - 2 months ago

Patented technology for slow release of topical formulations. Potentially the first single-active benzoyl peroxide to be approved as a prescription drug.

Benzinga - 2 months ago

Shares of Sol-Gel Technologies (NASDAQ:SLGL) moved higher by 0.1% after the company reported Q3 results. Quarterly Results Earnings per share increased 0.00% year over year to ($0.37), which b...

GlobeNewsWire - 2 months ago

NESS ZIONA, Israel, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing bra...

GlobeNewsWire - 2 months ago

NESS ZIONA, Israel, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializ...

GlobeNewsWire - 4 months ago

- PDUFA Goal Date Set for April 26, 2021

GlobeNewsWire - 4 months ago

NESS ZIONA, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercia...

GlobeNewsWire - 4 months ago

NESS ZIONA, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing ...

GlobeNewsWire - 5 months ago

NESS ZIONA, Israel, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing b...

GlobeNewsWire - 5 months ago

NESS ZIONA, Israel, July 29, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, dev...

GlobeNewsWire - 5 months ago

NESS ZIONA, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing b...

GlobeNewsWire - 6 months ago

Generic Product Collaborations between the Companies Now Cover Ten Products Generic Product Collaborations between the Companies Now Cover Ten Products

GlobeNewsWire - 7 months ago

NESS ZIONA, Israel, June 16, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, dev...

GlobeNewsWire - 8 months ago

NESS ZIONA, Israel, May 14, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing br...

GlobeNewsWire - 9 months ago

Investment is for ordinary shares and warrants to purchase ordinary shares at a combined price of $11 per ordinary share and accompanying warrants to purchase 0.80 of an ordinary share

GlobeNewsWire - 11 months ago

NESS ZIONA, Israel, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, dev...

GlobeNewsWire - 11 months ago

Successful topline results, strengthens Epsolay’s long-term safety and tolerability profile in the treatment of papulopustular rosacea

Seeking Alpha - 11 months ago

Sol-Gel Technologies: A Promising Small-Cap Dermatology Player In 2020

GlobeNewsWire - 11 months ago

NESS ZIONA, Israel, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”) a clinical-stage dermatology company focused on identifying, deve...

The Motley Fool - 11 months ago

The under-the-radar pharma company might have one of the industry's more promising approaches to dermatology treatments.

Seeking Alpha - 1 year ago

Sol-Gel Shines In Treating 2 Skin Disorders, NDAs Expected For Both Indications In 2020

GlobeNewsWire - 1 year ago

NESS ZIONA, Israel, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced the initiation of a Phase 1 proof of concept clinical study of SGT-210, its no...

The Motley Fool - 1 year ago

The small-cap company announced promising results from a clinical trial.

InvestorPlace - 1 year ago

Sol Gel Technologies (SLGL) news for Monday concerning an acne drug study with incredibly positive results has SLGL stock taking off. The post Sol Gel Technologies News: SLGL Stock Skyrockets ...

Benzinga - 1 year ago

Shares of the Israel-based, clinical-stage dermatology company Sol Gel Technologies Ltd (NASDAQ: SLGL) were more than doubling Monday.

Market Watch - 1 year ago

Shares of Sol-Gel Technologies Ltd. SLGL, -5.82% gained 154% in premarket trading on Monday after the Israeli drugmaker said its acne drug Twyneo met the primary endpoints in two late-stage tr...

GlobeNewsWire - 1 year ago

NESS ZIONA, Israel, Dec. 30, 2019 (GLOBE NEWSWIRE) --  Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced top-line results from two pivotal Phase 3 clinical trials for Twyneo®, an inv...

GlobeNewsWire - 1 year ago

NESS ZIONA, Israel, Oct. 16, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced it will present research on the use of its proprietary microencapsulation tech...

Zacks Investment Research - 1 year ago

Sol-Gel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Market Watch - 1 year ago

Sol-Gel Technologies Ltd. said Monday that two late-stage trials of a treatment for papulopustular rosacea produced positive results.

Zacks Investment Research - 1 year ago

Sol-Gel Technologies Ltd. (SLGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

About SLGL

Sol-Gel Technologies, a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, which has completed Phase II clinical trials for the treatment of acne vulgaris; Epsolay that has completed Phase II clinical trials for the treatment of papulopustular rosacea; SGT-210, a epidermal growth factor receptor inhibitor, which is in development for the treatmen... [Read more...]

Industry
Biotechnology
IPO Date
Jan 23, 2018
CEO
Alon Seri-Levy
Employees
61
Stock Exchange
NASDAQ
Ticker Symbol
SLGL
Full Company Profile

Financial Performance

In 2019, SLGL's revenue was $22.90 million, an increase of 17,655.04% compared to the previous year's $129,000. Losses were -$24.61 million, -23.58% less than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for SLGL stock is "Buy." The 12-month stock price forecast is 20.00, which is an increase of 94.36% from the latest price.

Price Target
$20.00
(94.36% upside)
Analyst Consensus: Buy